| CDC 
Immunization Advisory Panel Recommends H1N1 Influenza Vaccine Priorities, Starting 
with Pregnant Women 
 
  | The 
U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization 
Practices (ACIP) has announced that certain groups should be given priority for 
vaccination against novel influenza A-H1N1, also known as "swine flu." 
The list starts with pregnant women, who have an elevated risk of flu-related 
complications and death, according to a report in a recent issue of The Lancet. 
People with compromised immune systems -- which would include those with HIV/AIDS 
-- are also on the list. H1N1 vaccine candidates are now in the early stages of 
development and testing. | 
 
 
 By 
Liz Highleyman  Typical 
seasonal influenza mainly poses a risk for very young and elderly people and others 
with weak immune systems. The H1N1 flu, 
however, has caused an unusually high proportion of severe illness and death among 
older children and young adults (most of whom have had other underlying health 
conditions), and in particular pregnant women. 
 As of July 24, 2009, CDC 
had received reports of 43,771 laboratory-confirmed H1N1 cases, 5011 hospitalizations, 
and 302 deaths in the U.S.
 
 
  ACIP 
held a meeting in July to discuss the spread of H1N1 and to determine vaccination 
prioritization and implementation. When the H1N1 vaccine -- now undergoing intensive 
development -- first becomes available, ACIP recommends that programs and providers 
make it a priority to vaccinate the following groups: 
 |  | Pregnant 
women. |  |  | People 
who live with or care for children younger than 6 months of age. |  |  | Health 
care and emergency services personnel. |  |  | Persons 
between the ages of 6 months and 24 years. |  |  | People 
between the ages of 25 and 64 years who are at higher risk due to chronic health 
disorders or compromised immune systems. | 
 The 
advisory panel indicated that the key populations include people who are at higher 
risk of disease or complications, those who are likely to come in contact with 
novel H1N1, and those who could infect young infants. However, the agency's epidemiology 
figures indicate that the highest proportion of deaths -- 41% -- have occurred 
in people aged 25-49, followed by 24% in the 50-64 age group, neither of which 
are included in the priority list unless they have other health conditions. Only 
2% of deaths so far have occurred in children age 4 or younger.
 Altogether, 
the 5 highest priority groups comprise nearly 160 million people, which exceeds 
the projected initial vaccine supply. ACIP also released a narrower list -- comprising 
about 40 million people -- to be used if the vaccine has limited availability. 
This list includes pregnant women, household contacts of infants younger than 
6 months, a subset of health care workers and emergency personnel who have direct 
patient contact, children aged 6 months through 4 years, and children aged 5 to 
18 years who have underlying risk factors that put them at risk for flu complications.
 
 ACIP recommended that health care providers continue to emphasize the 
importance of regular seasonal influenza vaccination and ensure that patients 
receive these vaccines as soon as they become available -- particularly people 
aged 65 and older, who are not on the H1N1 vaccine priority list.
 "The 
H1N1 outbreak so far has spared that population to a large extent," said 
Anne Shuchat of the CDC's National Center for Immunization and Respiratory Diseases. 
"After younger age groups have been addressed, if supply is adequate vaccination 
could be offered at that time." For 
more information from the meeting and the resulting recommendations, visit the 
ACIP 
meeting website. Pregnant 
Women While 
the absolute number of pregnant women severely affected by H1N1 to date has been 
small, the percentage is high considering the proportion of pregnant women in 
the population at any given time. As 
reported in the August 
8, 2009 issue of The Lancet, 6 of the 45 H1N1-associated deaths reported 
to the CDC between April and June -- or 13% -- occurred among otherwise healthy 
pregnant women. Furthermore, pregnant women who contract H1N1 flu are at least 
4 times more likely to be hospitalized.  Pregnant 
women suspected of having H1N1 should receive oseltamivir (Tamiflu) as soon as 
possible, even before completion of diagnostic testing, according to the study 
authors.
 "Testing 
is not available in many instances and, when available, results of novel H1N1 
testing often takes several days," according to the CDC's interim guidance 
for pregnant women. "Clinicians should be aware of circulation of H1N1 in 
their area and not wait for test results to initiate influenza treatment in women 
who have symptoms consistent with influenza illness."
 "Some 
clinicians hesitate to treat pregnant women with antiviral medications because 
of concerns for the developing fetus, but this is the wrong approach," said 
lead author Denise Jamieson of CDC's U.S. Public Health Office. "It is critical 
that pregnant women in particular be treated promptly."  Global 
Epidemic
 In 
related news, the World Health Organization (WHO) in late July issued a report 
estimating that the novel H1N1 flu could infect as many as 2 billion people -- 
or about 1 in 3 worldwide -- over the next 2 years. The virus has now spread to 
all regions and almost every country, according to the agency. To 
address the crisis globally -- and ensure that limited vaccine and flu drug supplies 
do not all go to high-income countries -- United Nations Secretary-General Ban 
Ki-Moon urged wealthy nations to help developing countries access the H1N1 vaccine 
so that health workers can be vaccinated and able to keep hospitals open. During 
a recent Mercosur South American trade summit, presidents Cristina Kirchner of 
Argentina and Luiz Inacio Lula da Silva of Brazil proposed that developing countries 
be allowed to suspend patent rights so they can produce more H1N1 vaccine than 
licensed manufacturers can manage. Using patent rights to preserve an economic 
advantage, said Kirchner, "would condemn millions of people to death." Pharmaceutical 
company Baxter International announced on August 8 that it has completed production 
of its first commercial batches of H1N1 vaccine. The same day, Novartis announced 
that it has launched the first human trials of its candidate vaccine.The year-long 
trial will involve 6000 people in the U.S., U.K., and Germany. While 
efforts to develop, test, and produce an effective H1N1 vaccine have been put 
on the fast track, the WHO emphasized that this would not compromise safety or 
quality control. 8/18/09 Sources ACPM 
Headlines. CDC 
Advisory Panel Recommends H1N1 Vaccine Priority List. Press Release. 
August 6, 2009. Kaiser 
Family Foundation. H1N1 Could Infect Up To 2B People Within Next Two Years, WHO 
Says. Kaiser Daily Global Health Policy Report. July 27, 2009.  Kaiser 
Family Foundation. Fast-Tracked H1N1 Vaccines Will Not Compromise Safety, WHO 
Says. Kaiser Daily Global Health Policy Report. August 6, 2009. Reference DJ 
Jamieson, MA Honein, SA Rasmussen, and others. H1N1 2009 influenza virus infection 
during pregnancy in the USA. The Lancet 374(9688): 451-458. August 8, 2009. (Abstract). 
                                                     |